Analysts Predict Significant Upside for First Trust Health Care AlphaDEX Fund ETF
The latest analysis of the First Trust Health Care AlphaDEX Fund ETF (Symbol: FXH) shows promising upside potential based on its underlying holdings.
According to ETF Channel, the implied analyst target price for FXH is $128.17 per unit. Currently, the ETF trades at approximately $111.15. This pricing indicates a potential upside of 15.31%, based on analysts’ projections for its holdings.
Three notable holdings within FXH present significant upside to their analyst targets: Roivant Sciences Ltd (Symbol: ROIV), 10x Genomics Inc (Symbol: TXG), and Enovis Corp (Symbol: ENOV). ROIV, trading at $11.64, has an average analyst target of $17.05, reflecting a potential increase of 46.52%. For TXG, which is currently priced at $15.68, the average target is $22.23, suggesting a 41.80% upside. Meanwhile, ENOV trades at $46.91, with analysts expecting it to reach $66.50, translating to an upside of 41.76%. Below is a twelve-month price performance chart comparing ROIV, TXG, and ENOV:
A summary table of the current analyst target prices is as follows:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| First Trust Health Care AlphaDEX Fund ETF | FXH | $111.15 | $128.17 | 15.31% |
| Roivant Sciences Ltd | ROIV | $11.64 | $17.05 | 46.52% |
| 10x Genomics Inc | TXG | $15.68 | $22.23 | 41.80% |
| Enovis Corp | ENOV | $46.91 | $66.50 | 41.76% |
Are the analysts’ targets reasonable, or are they too optimistic? It’s essential for investors to consider if these forecasts are based on current market conditions and company performance updates. A higher target price can signal growth potential, but it may also suggest that analysts could be revising expectations downward. Investors should conduct thorough research to better understand these projections.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Highest Yield Preferreds
• UNL Average Annual Return
• PFFD shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
